Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET–Based Salvage Radiotherapy for Recurrent Prostate Cancer

Authors:

Abstract
Approximately 30% to 50% of patients with prostate cancer develop a biochemical relapse or prostate-specific antigen (PSA) persistence within the first 5 years after primary radical prostatectomy.1,2 Current international guidelines3 recommend early salvage radiotherapy (sRT) directed to the prostate bed with or without androgen deprivation therapy (ADT) in this disease setting; predictive nomograms are widely used to provide individualized estimates of biochemical relapse after sRT.4 However, prostate-specific membrane antigen positron-emission tomography (PSMA-PET) is increasingly used for staging patients with biochemical relapse or PSA persistence after radical prostatectomy,5 which affects the treatment decision process prior to delivery of sRT.6,7

This publication has 20 references indexed in Scilit: